✨ Your Portfolio is fetched and updated from zerodha.

Ipca Laboratories Ltd.

IPCALAB

Market Cap
₹40,142 Cr.
P/E
60.71

Ipca Laboratories Ltd.

  • Ipca Laboratories
  • Glaxosmithkline Phar
  • Glenmark Pharma
  • TJI Pharma
FAQs on Ipca Laboratories Ltd. Shareprice

Ipca Laboratories has given lower returns compared to its competitors.
Ipca Laboratories has grown at ~9.99% over the last 4yrs while peers have grown at a median rate of 25.93%

Yes, Ipca Laboratories is expensive.
Latest PE of Ipca Laboratories is 60.71, while 3 year average PE is 37.94.
Also latest EV/EBITDA of Ipca Laboratories is 27.57 while 3yr average is 21.97.

View FAQ's On Business
Growth Table
  • Ipca Laboratories Ltd.
  • Glaxosmithkline Phar
  • Glenmark Pharma
Balance Sheet
  • Ipca Laboratories Ltd.
  • Glaxosmithkline Phar
  • Glenmark Pharma
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Ipca Laboratories Ltd.
  • Glaxosmithkline Phar
  • Glenmark Pharma
Cash Flow
  • Ipca Laboratories Ltd.
  • Glaxosmithkline Phar
  • Glenmark Pharma
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Ipca Laboratories Ltd.
  • Glaxosmithkline Phar
  • Glenmark Pharma
Quarterly Results
  • Ipca Laboratories Ltd.
  • Glaxosmithkline Phar
  • Glenmark Pharma
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Ipca Laboratories Ltd. Financials

Balance sheet of Ipca Laboratories is strong.
It shouldn't have solvency or liquidity issues.

Yes, The debt of Ipca Laboratories is increasing.
Latest debt of Ipca Laboratories is ₹859 Crs as of Sep-24.
This is greater than Mar-24 when it was ₹794 Crs.

Yes, profit is increasing.
The profit of Ipca Laboratories is ₹670 Crs for TTM, ₹547 Crs for Mar 2024 and ₹471 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Ipca Laboratories latest dividend payout ratio is 18.54% and 3yr average dividend payout ratio is 17.18%

Companies resources are allocated to majorly productive assets like Plant & Machinery

View FAQ's On Shareholding
timeline Timeline
watchlist Watchlist
portfolio Portfolio
alerts Alerts
filter Research
filter Stock Screener
markets Market
raw materials Raw Material
Data feed provided by Accord Fintech